Biomedical Applications of Non-Small Cell Lung Cancer Spheroids.

Autor:	Rozenberg JM; Cell Signaling Regulation Laboratory, Moscow Institute of Physics and Technology (National Research University), Dolgoprudny, Russia.; Laboratory of Medical Informatics, Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia., Filkov GI; Laboratory of Medical Informatics, Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia.; Special Cell Technology Laboratory, Moscow Institute of Physics and Technology (National Research University), Dolgoprudny, Russia., Trofimenko AV; Special Cell Technology Laboratory, Moscow Institute of Physics and Technology (National Research University), Dolgoprudny, Russia., Karpulevich EA; Department of Information Systems, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia., Parshin VD; Clinical Center, Sechenov First Moscow State Medical University, Moscow, Russia., Royuk VV; Clinical Center, Sechenov First Moscow State Medical University, Moscow, Russia., Sekacheva MI; World-Class Research Center 'Digital Biodesign and Personalized Healthcare', Sechenov First Moscow State Medical University, Moscow, Russia., Durymanov MO; Laboratory of Medical Informatics, Yaroslav-the-Wise Novgorod State University, Veliky Novgorod, Russia.; Special Cell Technology Laboratory, Moscow Institute of Physics and Technology (National Research University), Dolgoprudny, Russia.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2021 Dec 07; Vol. 11, pp. 791069. Date of Electronic Publication: 2021 Dec 07 (Print Publication: 2021).
DOI:	10.3389/fonc.2021.791069
Abstrakt:	Lung malignancies accounted for 11% of cancers worldwide in 2020 and remained the leading cause of cancer deaths. About 80% of lung cancers belong to non-small cell lung cancer (NSCLC), which is characterized by extremely high clonal and morphological heterogeneity of tumors and development of multidrug resistance. The improvement of current therapeutic strategies includes several directions. First, increasing knowledge in cancer biology results in better understanding of the mechanisms underlying malignant transformation, alterations in signal transduction, and crosstalk between cancer cells and the tumor microenvironment, including immune cells. In turn, it leads to the discovery of important molecular targets in cancer development, which might be affected pharmaceutically. The second direction focuses on the screening of novel drug candidates, synthetic or from natural sources. Finally, "personalization" of a therapeutic strategy enables maximal damage to the tumor of a patient. The personalization of treatment can be based on the drug screening performed using patient-derived tumor xenografts or in vitro patient-derived cell models. 3D multicellular cancer spheroids, generated from cancer cell lines or tumor-isolated cells, seem to be a helpful tool for the improvement of current NSCLC therapies. Spheroids are used as a tumor-mimicking in vitro model for screening of novel drugs, analysis of intercellular interactions, and oncogenic cell signaling. Moreover, several studies with tumor-derived spheroids suggest this model for the choice of "personalized" therapy. Here we aim to give an overview of the different applications of NSCLC spheroids and discuss the potential contribution of the spheroid model to the development of anticancer strategies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Rozenberg, Filkov, Trofimenko, Karpulevich, Parshin, Royuk, Sekacheva and Durymanov.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu